Breakthrough Genomics, a leader in the clinical analysis of genomic data and early cancer diagnostics, announced today its collaboration with the PRECEDE Consortium to advance the clinical evaluation and adoption of its BT-Reveal™ Early Pancreatic Cancer Test. This groundbreaking blood test, which is powered by Singlera’s MethylTitan technology, can detect the earliest signs of pancreatic cancer in circulating cell-free DNA, often before symptoms appear. Utilizing patented DNA methylation technology, the test received the FDA’s coveted Breakthrough Device Designation and is currently available for high-risk patients through Breakthrough Genomics which operates a CAP and CLIA-certified clinical lab in Southern California.  The partnership with PRECEDE offers Breakthrough Genomics access to a network of the world’s foremost pancreatic cancer researchers, clinicians, and high-risk centers.